These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 7516779)
1. Interaction between bacteria and the lumenal bladder surface: modulation by pentosan polysulfate, an experimental and theoretical approach with clinical implication. Schamhart DH; de Boer EC; Kurth KH World J Urol; 1994; 12(1):27-37. PubMed ID: 7516779 [TBL] [Abstract][Full Text] [Related]
2. The effects of intravesical pretreatment with pentosan polysulfate on the bacillus Calmette-Guérin induced immune reaction of the guinea pig. De Reijke TM; De Boer LC; Steerenberg PA; Vos PC; Kurth KH; Schamhart DH J Urol; 1994 Mar; 151(3):746-9. PubMed ID: 7508528 [TBL] [Abstract][Full Text] [Related]
3. Mycobacterial adherence and BCG treatment of superficial bladder cancer. Schamhart DH; de Boer EC; Bevers RF; Kurth KH; Steerenberg PA Prog Clin Biol Res; 1992; 378():75-80. PubMed ID: 1284504 [TBL] [Abstract][Full Text] [Related]
4. Role of oral pentosan polysulfate in Bacillus Calmette-Guérin therapy in patients with non-muscle-invasive bladder cancer. Lee HY; Jung SI; Lim DG; Chung HS; Hwang EC; Kwon DD Investig Clin Urol; 2022 Sep; 63(5):539-545. PubMed ID: 36067999 [TBL] [Abstract][Full Text] [Related]
5. Intravesical treatment for interstitial cystitis/painful bladder syndrome: a network meta-analysis. Zhang W; Deng X; Liu C; Wang X Int Urogynecol J; 2017 Apr; 28(4):515-525. PubMed ID: 27614759 [TBL] [Abstract][Full Text] [Related]
6. Role of fibronectin in intravesical BCG therapy for superficial bladder cancer. Ratliff TL; Kavoussi LR; Catalona WJ J Urol; 1988 Feb; 139(2):410-4. PubMed ID: 3276931 [TBL] [Abstract][Full Text] [Related]
7. The fate of bacillus Calmette-Guerin after intravesical instillation. Durek C; Richter E; Basteck A; Rüsch-Gerdes S; Gerdes J; Jocham D; Böhle A J Urol; 2001 May; 165(5):1765-8. PubMed ID: 11342972 [TBL] [Abstract][Full Text] [Related]
8. Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder. Balemans LT; Vegt PD; Steerenberg PA; De Boer EC; Van Swaaij A; De Vries RE; Van der Meijden AP; Den Otter W Urol Res; 1994; 22(4):239-45. PubMed ID: 7871637 [TBL] [Abstract][Full Text] [Related]
9. Role of oral pentosan polysulphate in the reduction of local side effects of BCG therapy in patients with non-muscle-invasive bladder cancer: a pilot study. Yadav S; Tomar V; Yadav SS; Priyadarshi S; Banerjee I BJU Int; 2016 Nov; 118(5):758-762. PubMed ID: 27010115 [TBL] [Abstract][Full Text] [Related]
10. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. Chuang YC; Lee WC; Lee WC; Chiang PH J Urol; 2009 Oct; 182(4):1393-400. PubMed ID: 19683290 [TBL] [Abstract][Full Text] [Related]
11. Enhanced binding of modified pentosan polysulfate and heparin to bladder--a strategy for improved treatment of interstitial cystitis. Muthusamy A; Erickson DR; Sheykhnazari M; Bhavanandan VP Urology; 2006 Jan; 67(1):209-13. PubMed ID: 16413377 [TBL] [Abstract][Full Text] [Related]
12. Effect of local pentosan polysulphate pretreatment on the immune response to intravesical BCG. de Boer EC; Schamhart DH; Vos PC; Vleeming R; Kurth KH Investig Urol (Berl); 1994; 5():95-9. PubMed ID: 7536525 [No Abstract] [Full Text] [Related]
13. Polymerase chain reaction based method for the detection of BCG retention after intravesical instillation in guinea pig bladders. de Boer EC; Westerhof AC; Kolk AH; Kuijper S; Kurth KH; Schamhart DH Eur Urol; 2000 Apr; 37(4):488-93. PubMed ID: 10765082 [TBL] [Abstract][Full Text] [Related]
14. Morphological aspects of the interaction of Bacillus Calmette-Guérin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Teppema JS; de Boer EC; Steerenberg PA; van der Meijden AP Urol Res; 1992; 20(3):219-28. PubMed ID: 1615584 [TBL] [Abstract][Full Text] [Related]
16. [A Case Diagnosed as Iatrogenic Vesical Tuberculosis 4 Years after Intravesical Immunotherapy Using Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Carcinoma]. Kudo T; Iwasa N; Maeda S; Mitarai S Kansenshogaku Zasshi; 2016 Nov; 90(6):809-13. PubMed ID: 30277373 [TBL] [Abstract][Full Text] [Related]
17. Impaired immune response by isoniazid treatment during intravesical BCG administration in the guinea pig. de Boer EC; Steerenberg PA; van der Meijden AP; van Klingeren B; de Jong WH; Debruyne FM; Ruitenberg EJ Prog Clin Biol Res; 1992; 378():81-93. PubMed ID: 1301589 [TBL] [Abstract][Full Text] [Related]
18. Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Ratliff TL; Palmer JO; McGarr JA; Brown EJ Cancer Res; 1987 Apr; 47(7):1762-6. PubMed ID: 3545453 [TBL] [Abstract][Full Text] [Related]
19. [Intravesical bacillus Calmette-Guerin in the treatment of recurrent superficial bladder tumors]. Nakano M; Iwamuro S; Fujii H; Kondoh I Hinyokika Kiyo; 1988 Jun; 34(6):983-6. PubMed ID: 3223463 [TBL] [Abstract][Full Text] [Related]
20. Analysis of the immunologic mechanism of intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors: distribution and function of immune cells. Chung JY; Lee ES; Lee WJ; Kim HH; Min KJ; Lee C J Korean Med Sci; 1993 Apr; 8(2):135-44. PubMed ID: 8397930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]